PDEXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30

PRO DEX INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 3, 2026

$57.70−0.56 (-0.96%)

Close on Oct 19, 2026

Market cap: $193.98M
P/E (TTM): 14.0
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$77.55MFY2026, +19.1% a year since FY2012

Where these numbers come from

Parsed from the XBRL in Pro Dex's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3 reverse split on Jun 18, 2010
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PDEX.

Revenue growth16.5% · median 24.0%

Gross margin31.4% · median 63.5%

Operating margin16.8% · median -6.1%

Net margin17.6% · median -35.9%

Company	Revenue	Growth
PDEX	$77.55M	+16.5%
RCEL	$75.63M	+1.0%
CARL	$63.30M	+65.4%
APYX	$58.42M	+25.6%
KRMD	$45.11M	+22.4%
UTMD	$36.11M	–

Company

Next earnings (est.): Oct 29, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: June 30
Employees: 181
Held by institutions: 22.9%
Auditor: Baker Tilly US, LLP
SEC CIK: 788920

Advertisement
300 × 250